The expansion of the partnership with Grovet to include exclusive distribution rights in 27 European countries is a significant strategic move for Zomedica. This is likely to increase the company's market penetration and sales in Europe, positively impacting its stock price in the short term. The immediate market reaction, with shares rising 2.53%, reflects investor optimism about the potential growth and revenue opportunities from this partnership.